2022 Fiscal Year Final Research Report
The role of endothelin in COPD
| Project/Area Number |
20K17181
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 53030:Respiratory medicine-related
|
|---|
| Research Institution | Kobe University |
|---|
Principal Investigator |
Umezawa Kanoko 神戸大学, 医学研究科, 医学研究員 (40824181)
|
|---|
| Project Period (FY) |
2020-04-01 – 2023-03-31
|
| Keywords | COPD / エンドセリン |
|---|
| Outline of Final Research Achievements |
Pulmonary hypertension is one of the major complications of chronic obstructive pulmonary disease (COPD), and pulmonary hypertension and right heart failure are known to be poor prognostic factors.
At first we examined changes in plasma endothelin (ET-1) before and after the start (change) of inhaled drugs in COPD patients, we found that ET-1 in plasma decreased after the start of inhalation. In an elastase-induced COPD mouse model, plasma ET-1 levels were significantly elevated in the elastase-treated group (p<0.01). Treatment effects of budesonide/formoterol/glycopyrronium, etc. were observed in this COPD model, and significant reductions in ET-1 concentration were observed in all treatment groups (p<0.05).
|
| Free Research Field |
呼吸器内科
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究は、①既存の吸入薬の肺高血圧への進展抑制効果を明らかにすること、②肺高血圧の進展に重要な役割を果たしているエンドセリンがCOPDの肺高血圧症への進展に果たす役割を明らかにしていくこと、さらに③COPD患者の呼気凝集液検体を用いてエンドセリンの定量を行うことで、COPDに対するこれらの治療がエンドセリンに与える効果を調べることを主な目的にしている。本研究によって現在有効な薬物治療がない肺疾患を原因とする肺高血圧症への治療法が確立し、有病率の高いCOPDの生命予後改善に寄与すると期待される
|
